Aardvark Rules Out Restarting Terminated Phase 3 Trials

Aardvark Therapeutics Inc (NASDAQ: AARD) told investors it has no plans to resume its recently terminated phase 3 trials "as previously designed" after cutting its workforce, with shares at $6.91, down 3.89% on the day as of 15:19 GMT on 12 August 2026.

Aardvark Therapeutics Inc (NASDAQ: AARD) has closed the door on the late-stage program it halted, telling investors it has no intention of restarting the recently terminated phase 3 trials "as previously designed." The confirmation follows a reduction in the company's workforce and leaves a smaller organization working to identify what, if anything, comes next for a pipeline that is now stalled.

Shares changed hands at $6.91, down 3.89% on the day, having traded between $6.89 and $7.54 and closed the prior session at $7.19, as of the last trade at 15:19 GMT on 12 August 2026. That decline came on a day when the broad market was firm: the S&P 500 tracker (SPY) was up 0.19% at $772.03 and the Nasdaq 100 tracker (QQQ) up 0.79% at $724.13, while the Dow 30 tracker (DIA) was essentially flat at $537.15, down 0.02%. Aardvark is moving against, not with, the tape.

Why "as previously designed" is the phrase that matters

Companies that pause a trial often leave themselves room to restart it. Aardvark's language does the opposite work. Saying the studies will not resume in their prior form tells investors that the protocol itself — the endpoints, the enrollment criteria, the dosing scheme, or some combination — is not something management intends to pick back up. Any future late-stage effort would have to be re-specified, which in practice means new design work, new regulatory conversations and new money before a single patient is dosed.

That is a materially different proposition from a temporary hold. A hold preserves the sunk investment in a trial and the timeline attached to it. A termination with no restart resets both to zero. For a clinical-stage biotech, the timeline is often the asset, because it is what a partner or an acquirer is buying.

The detail was confirmed by Fierce Biotech, which reported the company's message to investors as the wait for concrete next steps stretches on.

The headcount cut came first, and it is the tell

Sequencing matters here. Aardvark slimmed down its workforce before confirming that the phase 3 studies were finished. In clinical-stage biotech, staffing is closely coupled to activity: clinical operations, medical affairs, regulatory and manufacturing headcount all exist to service specific trials. Cutting people ahead of a formal pipeline decision usually signals that the decision has already been made internally, and that management is preserving cash while it works out how to communicate the strategy.

Reductions of this kind are also a runway exercise. Personnel and trial costs are the two largest line items for a company at this stage, and removing one while eliminating the other buys months of optionality. What it does not buy is a new asset. A slimmed-down organization has fewer people available to design a replacement study, run a new indication, or execute a business development process — which is why smaller biotechs in this position frequently end up exploring strategic alternatives rather than rebuilding.

What a stalled pipeline does to the equity story

Clinical-stage biotech valuation is fundamentally a probability calculation: the chance a lead asset reaches market, multiplied by what it would be worth, discounted back and set against the cash on hand. When the phase 3 leg of that calculation is removed and not replaced with a defined alternative, the market tends to default to a cash-based valuation, marking the equity closer to what the balance sheet holds than to what the science might one day deliver.

The 3.89% move on the day is modest by biotech standards — this is not the double-digit gap that typically follows an unexpected trial termination. That is consistent with the news having been largely absorbed already: the workforce reduction and the trial terminations were known, and Wednesday's confirmation removed a residual possibility rather than introducing a surprise. The stock's intraday slide from $7.54 to $6.89, however, shows sellers were active on the update.

Investors weighing the name from here are effectively asking three questions. How much cash is left, and how long does the reduced cost base make it last? Is there a preclinical or early-clinical asset worth re-prioritizing? And is management pointed toward a partnership, a reverse merger, or a wind-down? None of those has been answered publicly.

Where this sits in the current biotech cycle

Aardvark's predicament is a familiar one in this market. Capital for clinical-stage companies without near-term data has been selective, and the response to a late-stage setback has increasingly been to shrink first and decide later — protecting the balance sheet so that whatever comes next is a choice rather than a forced sale. The companies that recover from this position generally do so on the strength of a second asset that was already in the building, or through a transaction that hands the listing to someone else's pipeline.

The pressure point is time. "Working to find a path forward" is not a plan, and every month it remains unspecified is a month of cash burn against an unchanged risk profile. Management has bought itself room with the headcount cut; it has not yet shown what it intends to buy with that room.

What to watch next

• The next cash disclosure. The size of the balance and the stated runway will do more to set the share price than any pipeline language.
• A named replacement asset. Re-prioritizing an existing program would restore a probability-weighted case; silence would not.
• Strategic-alternatives language. If that phrase appears in a filing, the conversation shifts from drug development to what the shell and the cash are worth.
• Further restructuring. A second round of cuts would signal that the first was sized for a plan that has since changed.

For now, the position is unambiguous on one point only: the phase 3 trials Aardvark started are not coming back in the form they were written. Everything else about the company's future remains open.

Key facts

• AARD share price: $6.91, -3.89%, as of 15:19 GMT 12 Aug 2026
• Prior close / day range: $7.19; traded $6.89–$7.54
• Pipeline status: Phase 3 trials terminated; no plans to resume 'as previously designed'
• Cost action: Workforce reduced ahead of the pipeline confirmation

Frequently asked questions

What did Aardvark Therapeutics announce?

Aardvark confirmed to investors that it is walking away from phase 3 trials that had recently been terminated, stating it has no plans to resume the studies "as previously designed." The confirmation followed a reduction in the company's workforce, and management said it is working to find a path forward for its stalled pipeline.

How did Aardvark shares react?

Aardvark Therapeutics Inc (NASDAQ: AARD) traded at $6.91, down 3.89% on the day, as of the last trade at 15:19 GMT on 12 August 2026. The prior close was $7.19 and the stock ranged between $6.89 and $7.54 during the session, moving lower while the broader US market was flat to higher.

Why does the phrase 'as previously designed' matter?

It signals the trial protocol itself will not be revived. A pause preserves the design, the enrolled patients and the timeline. Ruling out a restart in the prior form means any future late-stage work would need fresh design, new regulatory discussion and new funding, effectively resetting the program's clock and cost to the beginning.

What does a workforce reduction indicate at a clinical-stage biotech?

Staffing at these companies is tied to specific trial activity — clinical operations, regulatory and manufacturing roles exist to run studies. Cutting headcount before formally confirming a pipeline decision usually means the decision was already taken internally, and management is conserving cash while it determines and communicates a revised strategy.

How was the wider market trading that day?

Benchmarks were mixed to positive as of 15:19 GMT on 12 August 2026. The S&P 500 tracker SPY was up 0.19% at $772.03, the Nasdaq 100 tracker QQQ rose 0.79% to $724.13, and the Dow 30 tracker DIA was effectively unchanged at $537.15, down 0.02%. Aardvark's decline was company-specific.

What should investors watch from Aardvark next?

The key signals are the next cash balance and runway disclosure, whether management names a replacement asset to prioritize, and any appearance of "strategic alternatives" language in filings, which would shift the discussion toward a partnership, reverse merger or wind-down. Further restructuring would suggest the original cuts were sized for a plan that has changed.

Sources

• After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags on — Fierce Biotech

Photo: SHVETS production · Pexels Licence — source